Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Trial Profile

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2012

At a glance

  • Drugs Ponesimod (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 20 Jul 2010 Results are expected in the second half of 2011, according to an Actelion Pharmaceuticals.
    • 14 Nov 2009 Actual patient number (66) added as reported by ClinicalTrials.gov.
    • 13 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top